Results
tumor, CRC, PD, BOR, TRAEs
DISEASE, MAY, TUMOR, ADVERSE EVENTS
As of May 15, 2020, 32 patients with advanced CRC had received bintrafusp alfa for a median duration of 7.1 (range, 2.0-100.0) weeks. Median follow-up was 185 (range, 3-185) weeks. All patients had discontinued treatment by the data cutoff. Overall, 87.5% of patients had  ≥ 3 prior anticancer therapies, and 81.3% had  < 1% tumor PD-L1 expression (In the 30 evaluable patients, 1 had a confirmed partial response (PR), 1 had stable disease, and 28 had PD as BOR per IRC ((Any grade treatment-related adverse events (TRAEs) occurred in 68.8% of patients; grade 3 occurred in 12.5% (Treatment-related adverse events.